Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights.
The technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells.
This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies.
“We are pleased to now own this technology and look forward to applying it in future exosome AAV programs,” said Per Lundin, Chief Business Officer & Co-Founder of Evox Therapeutics. “This is part of our long-term business strategy of leveraging exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”.
Exosome-based drugs have the potential to address some of the limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies.
